Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00138528

Enrollment

Registered

2005-08-30

Start date

2004-10-31

Completion date

2006-02-28

Last updated

2017-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Keywords

Metabolic Syndrome, fluvastatin

Brief summary

Other effects of fluvastatin are investigated in German patients with metabolic syndrome.

Interventions

DRUGFluvastatin

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Written informed consent * Male and female patients, aged between 18 and 75 years * Metabolic syndrome according to National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII)

Exclusion criteria

* History of heart failure * HIV positive * Stroke Other protocol defined inclusion and

Design outcomes

Primary

Measure	Time frame
Change from baseline in circulating marker of inflammation (C-reactive protein) after 5 weeks	—

Secondary

Measure	Time frame
Change from baseline in low density lipoprotein cholesterol after 5 weeks	—
Change from baseline in non high density lipoprotein cholesterol after 5 weeks	—
Change from baseline in total cholesterol after 5 weeks	—
Change from baseline in high density lipoprotein cholesterol after 5 weeks	—
Change from baseline in oxidized low density lipoprotein cholesterol after 5 weeks	—

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026